Cargando…
Claims about the safety and efficacy of early treatment of COVID-19 with hydroxychloroquine and azithromycin must be supported by real evidence
Autores principales: | Bigna, Jean Joel, Kamtchum-Tatuene, Joseph, Noubiap, Jean Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516577/ https://www.ncbi.nlm.nih.gov/pubmed/32980540 http://dx.doi.org/10.1016/j.tmaid.2020.101886 |
Ejemplares similares
-
Neurologic complications of sickle cell disease in Africa: A systematic review and meta-analysis
por: Noubiap, Jean Jacques, et al.
Publicado: (2017) -
Neurological complications of sickle cell disease in Africa: protocol for a systematic review
por: Mengnjo, Michel K, et al.
Publicado: (2016) -
Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients
por: Alizargar, Javad
Publicado: (2020) -
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database
por: Nguyen, Lee S., et al.
Publicado: (2020) -
Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”
por: Bonny, Aimé, et al.
Publicado: (2020)